FindTrial
Sign In

Synflorix

BIOLOGICAL13 trials

Sponsors

GlaxoSmithKline, Menzies School of Health Research, PATH, Public Health England

Conditions

CoughFebrile IllnessImmunizationInfections, RotavirusInfections, StreptococcalLower Respiratory Tract InfectionOtitis MediaPneumonia, Pneumococcal

Phase 1

Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
CompletedNCT02097472
PATHPneumonia, Pneumococcal
Start: 2014-04-30End: 2015-12-31Updated: 2019-10-10

Phase 2

Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule
CompletedNCT00513409
GlaxoSmithKlineInfections, Streptococcal
Start: 2007-08-22End: 2008-08-28Updated: 2018-12-19
Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants
CompletedNCT01204658
GlaxoSmithKlineInfections, Streptococcal
Start: 2010-09-27End: 2012-10-01Updated: 2019-05-29

Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
CompletedNCT00345358
GlaxoSmithKlineInfections, Streptococcal
Start: 2006-09-18End: 2007-11-15Updated: 2019-01-15
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
CompletedNCT00370396
GlaxoSmithKlineInfections, Streptococcal
Start: 2006-09-25End: 2007-11-06Updated: 2019-06-10
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age
CompletedNCT00489554
GlaxoSmithKlineInfections, Streptococcal, Streptococcus Pneumoniae Vaccines
Start: 2007-07-03End: 2008-03-31Updated: 2020-01-13
Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age
CompletedNCT00533507
GlaxoSmithKlineInfections, Rotavirus
Start: 2007-09-18End: 2008-06-06Updated: 2018-06-08
Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines
CompletedNCT00547248
GlaxoSmithKlineInfections, Streptococcal
Start: 2007-10-22End: 2008-10-07Updated: 2019-01-14
Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants
CompletedNCT03197376
PATHPneumonia, Pneumococcal
Start: 2017-06-21End: 2019-05-09Updated: 2020-07-14
Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants
CompletedNCT03896477
PATHPneumonia, Pneumococcal
Start: 2019-07-18End: 2020-12-17Updated: 2022-04-20

Phase 4

Pneumococcal Vaccines Early and in Combination
CompletedNCT01174849
Menzies School of Health ResearchOtitis Media
Start: 2011-08-31End: 2018-03-15Updated: 2018-10-18
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life
CompletedNCT01735084
Menzies School of Health ResearchCough, Febrile Illness, Lower Respiratory Tract Infection +2
Start: 2013-03-12End: 2019-10-03Updated: 2020-03-25
Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants
WithdrawnNCT02918708
Public Health EnglandImmunization, Vaccination
Updated: 2019-08-28

Related Papers

Booster Vaccination against Yellow Fever in Gambian children-(BoVY) -a Phase 3 clinical trial to establish safety and immunogenicity of repeated YF vaccination in healthy Gambian children of different ages.
2024-12-241 citations
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules
PLoS Medicine2024-06-034 citations
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
2023-01-108 citations
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
2022-06-2710 citations
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
2021-03-089 citations
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
2021-01-2827 citations
10-Valent pneumococcal non-typeable <i>H. influenzae</i> protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
BMJ Open2020-05-017 citations
Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study
Vaccine2018-07-2517 citations
Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea.
2017-12-257 citations
Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
2017-07-1717 citations
Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies
Human Vaccines & Immunotherapeutics2016-10-137 citations
Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial
BMJ Open2015-01-0127 citations
Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
2011-11-0116 citations